PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-09-13 | Pages: 200+ | Report ID: WR-2024-09-13-49475 | Pharmaceutics
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Preimplantation Genetic Diagnosis (PGD) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET
7.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Illumina
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Takara Bio
16.3 PerkinElmer
16.4 Thermo Fisher
16.5 Natera
16.6 Agilent Technologies
16.7 Yikon Genomics
16.8 Abbott Laboratories
16.9 Coopersurgical
16.10 Oxford Gene Technology
16.11 Combimatrix
16.12 Quest Diagnostics
16.13 Progenesis
16.14 Genea Limited
16.15 Invicta Genetics
16.16 Beijing Genomics Institute
16.17 Bioarray
16.18 Invitae
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Chromosomal Abnormalities
Gender Selection
X-linked Diseases
Aneuploidy
Single Gene Disorders
Others
Market by Application :
Maternity Centers & Fertility Clinics
Hospitals, Diagnostic Labs, and Service Providers
Research Laboratories & Academic Institutes
Companies
Illumina
Takara Bio
PerkinElmer
Thermo Fisher
Natera
Agilent Technologies
Yikon Genomics
Abbott Laboratories
Coopersurgical
Oxford Gene Technology
Combimatrix
Quest Diagnostics
Progenesis
Genea Limited
Invicta Genetics
Beijing Genomics Institute
Bioarray
Invitae
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.